February 13, 2025

Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

Researchers of the Heidelberg University, Heidelberg University Hospital (UKHD) and Heidelberg Institute for Theoretical Studies (HITS) have developed a synthetic peptide based on the natural protein S100A1, a nearly universal “fuel” for weakened hearts. The researchers combined computer-aided methods with lab studies to investigate the therapeutic effect of the so called S100A1ct peptide molecule. The results have been published in the journal “Circulation”.

Source: Heidelberg University Hospital

The “Molecular and Cellular Modeling” group led by Rebecca Wade was part of the project. The approach was to integrate experiments on heart muscle cells and animals and computational molecular modeling. “Our lab developed a customized computer-aided modeling pipeline for this project to model the molecular structure of the peptide and interactions with the predicted molecular effectors in the diseased heart cells”, Wade says. “The computational modeling guided the design of specific experiments to investigate the molecular mechanisms.”

The framework for the successful cooperation was provided by the Informatics for Life (I4L) Initiative, which was funded by the Klaus Tschira Foundation. The project received further financial support from the German Center for Cardiovascular Research with translational project funding from the Federal Ministry of Education and Research from the “Preclinical Confirmatory Studies” program.

For more information see the press release of the Heidelberg University Hospital:
https://www.klinikum.uni-heidelberg.de/newsroom/en/therapeutic-designer-peptide-to-combat-acute-heart-muscle-weakness/

Publication:

Kehr D, Ritterhoff J, Glaser M, et al. S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models. Circulation. Published online November 21, 2024. doi:10.1161/CIRCULATIONAHA.123.066961

Scientific Contact:

Prof. Dr. Patrick Most 
Division of Molecular and Translational Cardiology
Department of Internal Medicine III 
Heidelberg University Hospital
Heidelberg Medical Faculty of Heidelberg University
patrick.most@med.uni-heidelberg.de

Prof. Dr. Rebecca Wade
Group Leader `Molecular and Cellular Modeling´
Heidelberg Institute for Theoretical Studies (HITS)
Center of Molecular Biology of Heidelberg University (ZMBH)
Heidelberg Medical Faculty of Heidelberg University

Press Contact:
Dr. Stefanie Seltmann
Head of Communications
Heidelberg University Hospital (UKHD)
presse@med.uni-heidelberg.de

Dr. Peter Saueressig
Head of Communications
Heidelberg Institute for Theoretical Studies (HITS)
comms@h-its.org

Our latest News

discover more
Globally influential: Professor Auffarth once again on ophthalmology’s “Power List”

Globally influential: Professor Auffarth once again on ophthalmology’s “Power List”

Professor Dr. Gerd Auffarth continues to be one of the world’s leading ophthalmologists, according to “The Ophthalmologist”. The journal has now published its “Power List 2025” of the most influential representatives of the field. The Medical Director of the Eye Clinic at Heidelberg University Hospital (UKHD) has now been named on the list for the […]

3D bioprinting: NMI, TU Darmstadt and Black Drop develop improved bioink

3D bioprinting: NMI, TU Darmstadt and Black Drop develop improved bioink

Joint press release by the NMI and the Technical University of Darmstadt (How) can we 3D print tissues that mimic the complex anatomy of natural body tissue as closely as possible? 3D bioprinting is a great hope in the field of regenerative medicine to produce miniaturized tissues and organ precursors with biological functionality. Today, however, […]

Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 — VERAXA Biotech AG(“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp